Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04329039 · ClinicalTrials.gov registry record · Phase 2
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
A Phase 2 study of Pancreatic Diseases, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT04329039 is a Phase 2 study of Pancreatic Diseases that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 103 participants, below the 1,168-participant average among 5 other Pancreatic Diseases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04329039, a Phase 2 study of Pancreatic Diseases, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are trying to determine how the length of antibiotic treatment in addition to octreotide after pancreatic surgery affects the amount of time subjects are hospitalized as well as how many subjects develop pancreatic fistulas.
Conditions Studied
Interventions
- DRUG Somatostatin analog
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04329039
The ClinicalTrials.gov registry entry for NCT04329039 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,168-participant average among 5 other Pancreatic Diseases trials with a reported enrollment target (91% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Diseases appearing as the primary indexed condition, and to 1 intervention - of which Somatostatin analog is the first listed.
NCT04329039 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04329039 about?
NCT04329039 is a clinical study titled "Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics". Researchers are trying to determine how the length of antibiotic treatment in addition to octreotide after pancreatic surgery affects the amount of time subjects are hospitalized as well as how many subjects develop pancreatic fistulas.
What is the current status of trial NCT04329039?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2020-11-17. Estimated completion is 2026-12-31.
What conditions does trial NCT04329039 study?
This clinical trial studies the following conditions: Pancreatic Diseases.
What interventions are being tested in trial NCT04329039?
The interventions under investigation include: Somatostatin analog (DRUG).
Who is sponsoring clinical trial NCT04329039?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04329039 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
UCSF PANC Cyst Registry
RECRUITING
-
Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
RECRUITING
-
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
RECRUITING
-
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
COMPLETED · Phase 3
-
Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.